Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lumena Pharmaceuticals

Request full access

Shire: A Global Innovator in Specialty Biopharmaceuticals

San Diego, United StatesFounded 2011Biotech & Life Sciences

About Lumena Pharmaceuticals

Lumena Pharmaceuticals, Inc. operated as a biopharmaceutical firm with a clear focus on developing treatments for rare and severe liver diseases. Founded in 2011 by Pappas Ventures, the company was established to address cholestatic liver diseases, which are characterized by impaired bile acid flow that leads to progressive liver damage. The leadership team included President and CEO Mike Grey, a venture partner at Pappas Ventures with prior experience as CEO of SGX Pharmaceuticals, which was acquired by Eli Lilly & Co. in 2008. The management team's extensive experience was a key factor in advancing the company's clinical programs.

The company's core business revolved around its two main product candidates, LUM001 and LUM002. Both were orally administered inhibitors of the apical sodium-dependent bile acid transporter (ASBT), a protein responsible for recycling bile acids from the intestine back to the liver. By blocking this transporter, the drugs aimed to reduce the absorption of bile acids, thereby lowering their concentration in the liver and bloodstream. This mechanism was intended to slow disease progression, improve liver function, and alleviate debilitating symptoms like severe itching (pruritus) for patients with these conditions. Lumena's target market consisted of pediatric and adult patients suffering from rare cholestatic liver diseases such as Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Additionally, LUM002 was being developed for nonalcoholic steatohepatitis (NASH), a more common metabolic disorder.

Lumena's journey was marked by significant financial and clinical milestones. The company secured $23 million in a Series A financing round in 2013, followed by a $45 million Series B round in 2014 led by New Enterprise Associates. These funds were crucial for advancing the clinical development of its lead candidates. In a strategic move that highlighted the potential of its pipeline, Lumena Pharmaceuticals was acquired by Shire plc in May 2014 for an upfront payment of $260 million, with additional near-term milestone payments. This acquisition was a strategic fit for Shire, strengthening its rare disease portfolio and complementing its existing gastrointestinal business. The deal provided Shire with LUM001, then in Phase 2 trials for four orphan indications, and LUM002, which was ready to enter Phase 2. The acquisition was seen as a positive outcome for investors and, most importantly, for patients with rare cholestatic liver diseases.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
1
Open positions
None listed
Dealroom signal
60.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Brokerage, Disease, Auction, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing May 2014 $260M $260M Shire —
SERIES BOther financing Mar 2014 $45M $180M Pappas Capital · Alta Partners · RiverVest Venture Partners · RA Capital Management —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Lumena Pharmaceuticals website traffic

Latest recorded traffic for Lumena Pharmaceuticals is 1.1K monthly website visits, up 74.6% over the last three months. Lumena Pharmaceuticals's team declined 50% over the past year.

Latest monthly visits1.1K 3-month web change+74.6% 1-year team growth-50%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Lumena Pharmaceuticals in the San Diego ecosystem

Live from Dealroom

The Lumena Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Other known investors1 additional known investor

  • Shire
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lumena Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lumena Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.